印孚瑟斯：2025 AI商业价值雷达报告：生命科学行业版（英文版）（24页）.pdf

1、AI BUSINESS VALUE RADAR:LIFE SCIENCES EDITION#BreakthroughsForLife2AI Business Value Radar:Life Sciences Edition|External Document 2025 Infosys LimitedKnowledge InstituteKnowledge Institute2AI Business Value Radar:Life Sciences Edition|External Document 2025 Infosys Limited3 External Document 2025 I

2、nfosys Limited|AI Business Value Radar:Life Sciences EditionKnowledge InstituteTable of contentsKnowledge InstituteIntroduction 4Where AI works 6AI requires transformation,investment 10The workforce opportunity 12Spend,transform,train 16Appendix A:Use case types used in the survey 17Appendix B:Resea

3、rch approach 20Contributors 213 External Document 2025 Infosys Limited|AI Business Value Radar:Life Sciences Edition4AI Business Value Radar:Life Sciences Edition|External Document 2025 Infosys LimitedKnowledge InstituteLife sciences companies are ahead of the pack in achieving value from artificial

4、 intelligence(AI),according to a new Infosys study.We surveyed 3,798 business leaders for the Infosys AI Business Value Radar and found that about 20%of AI use cases deliver on all business objectives,and 30%of use cases deliver on some objectives.(See Appendix A for methodology and more details on

5、use cases studied.)Focusing specifically on life sciences operations,we found that 28%of AI use cases deliver on all business objectives(vs.19%across all industries)and an additional 37%(vs.32%)have delivered on some objectives.Life sciences organizations have achieved more positive impact from AI,c

6、anceled fewer AI projects,and had fewer AI use cases in the sandbox(Figure 1).Thats better than practically all other industries.Life sciences companies have typically lagged in adopting new technologies.Extensive regulatory approvals for new software and processes limit how pharmaceutical organizat